Antidote of carbon monoxide and method of its application

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to zinc-containing antidote of lethal and severe poisonings with carbon monoxide. Claimed antidote represents intramolecular tricyclic complex of triethanolamine with zinc salts of inorganic or organic acids (2, 8, 9-trihydrozincatrane) with ratio of triethanolamine to zinc salts being 1:1. Invention also relates to method of protection against poisoning by carbon monoxide by peroral introduction into organism of zinc-containing antidote in 5 vol. % ethanol in dose range 20-60 mg/kg of body weight.

EFFECT: prevention of lethal poisoning with carbon monoxide, higher efficiency and reducing acute toxicity of zinc-containing antidote.

9 cl, 5 ex.

 

The invention relates to medicine and aims to create original antidote for protection and prevention of fatal, serious and not so significant poisoning carbon monoxide (carbon monoxide, CO).

Known antidote carbon monoxide - cytochrome C, the mechanism of therapeutic action is based on reimbursement of tissue endogenous cytochrome C (Gangara PS tutorial on clinical toxicology / Pssenger, AA Novikov - M.: Medicine, 1979. - 336 S.).

It also indicates that the protective effect when CO poisoning is called zinc compounds. The use of antidotes, including this metal is suitable because of their low toxicity.

Described antidote CO - complex of bis-(1-vinylimidazole) with zinc dichloride (A.S. No. 1822155 SU, IPC6C07F 3/06, publ. 09.02.1995). He received one-step way interaction of hard-to-1-vinyl-imidazole with zinc dichloride (2:1 ratio) in ethanol at room temperature. The original ligand was synthesized by the reaction of imidazole with acetylene under pressure.

The protective action of the antidote in case of poisoning CO studied male white mice under the conditions of dynamic dose of carbon monoxide (concentration of 15 mg/l or 1.2% in air) in the seed chamber for 20 minutes Control animals were present in each seed. Take into account on italmost life for each dead animal.

This antidote at a concentration of FROM 15 mg/l in a wide dose range (30-80 mg/kg) increases the lifespan of 14%, and the survival rate at 28% of the animals. When reducing the concentration of CO in the experience of up to 5 mg/l and increase the duration of poisoning from 20 to 180 min complex of 1-vinyl-imidazole with ZnCl2(dose 50 mg/kg) increases the life span of experimental animals to 46% (survival rate to 52.5%).

The disadvantage of this antidote is its relatively high toxicity and low solubility in water. Source heterocyclic reactant synthesized by sophisticated technology, coupled with the need for the use of acetylene under high pressure.

The prototype application is the antidote WITH bis(1-vinylimidazole)zinc-diacetate complex of 1-vinylimidazole with zinc diacetate composition of 2:1 (patent No. 2070201 (EN, IPC6C07F 1/00, publ. 10.12.1996). In the patent included and how it is used.

This antidote receive the one-stage method based on the interaction of 1-vinylimidazole with the diacetate of zinc in the environment of acetone and ether at room temperature.

Test the protective effects of bis(1-vinylimidazole)zincdiacetate from fatal poisoning carbon monoxide conducted on white mice, control animals were present in each seed. The experiments were carried out under the conditions of dynamic seed CO (conc. 15 mg/l is whether to 1.2% in air) in the seed chamber for 20 minutes.

Antidote dose of 50 mg/kg of body weight of the animal was injected intraperitoneally 45 minutes before the seed in the form of aqueous solution or suspension, stabilized by tween-80.

The effectiveness of the antidote was controlled by determining the length of life for each dead animal, and the calculation of life expectancy (min) and survival (%) animals. Control animals were injected with isotonic sodium chloride equivalent volume (0.2 ml liquid at 20 g weight).

It is shown that bis(1-vinylimidazole)cindicates the standard seed in the dose ensures the survival of 62.5% of the experimental animals and the duration of their life of 13.1 minutes

In the study of protective, preventive actions bis(1-vinyl-imidazole)zincdiacetate poisoning low concentrations of carbon monoxide animals were subjected to dynamic priming at CO concentrations of 0.004 and 0.008 mg/L. One-third of the animals pre-injected 60 mg/kg antidote in the form of an aqueous solution intraperitoneally, another third to 30 mg/kg, the rest of the same volume of saline (control). Through 1-1,5 hours in animals was determined by the concentration of carbon-shemoglobin in the blood. Our data indicate that bis(1-vinylimidazole)cindicates has a protective preventive effect and poisoning low conc is of CO, reducing the concentration of carboxyhemoglobin in the blood more than twice compared to control.

The complex of 1-vinylimidazole with zinc diacetate significantly exceed protective action above described complex of 1-vinylimidazole with zinc dichloride and has a number of additional advantages because of its higher water solubility and lower toxicity LD50780 (609-998) mg/kg

The disadvantages of this prototype are still quite high toxicity of bis(1-vinylimidazole)zincdiacetate, the need to use for the synthesis of difficult and expensive 1-vinylimidazole using ognestrelnogo acetylene under pressure and toxic, hazardous, flammable solvents (ether and acetone).

The General object of the present invention is the development of synthetically readily available zinc antidote for protection against poisoning by carbon monoxide, with the aim of expanding the range simplest way to obtain and more effective drugs, not shown in the treatment of side effects.

The technical result of the invention is to prevent death by poisoning carbon monoxide, increasing efficiency and reducing acute toxicity antidote, a significant improvement of technology the technology of its production and improve its safety and efficiency.

The shortcomings of the prototype and the achievement of the claimed technical result from the application of the new antidote, anti-poisoning carbon monoxide is the use of 2,8,9-trihydrochloride complex of Tris(2-hydroxyethyl)amine (triethanolamine) with a zinc salt of an inorganic or organic acid composition is 1:1, which meets the General formula N(CH2CH2OH)3ZnX2or N(CH2CH2OH)3ZnY, where X is the anion monobasic, a Y - anion dibasic acid.

Comparative analysis of the prototype and patent-pending antidote of carbon monoxide indicates that they are zinc-containing compounds.

A distinctive feature of patentable antidote of carbon monoxide is that it is a 2,8,9-digitalnature - intramolecular tricyclic complex of Tris(2-hydroxyethyl)amine (triethanolamine) with zinc salts of inorganic or organic acid composition is 1:1.

The shortcomings of the prototype and the achievement of the technical result from the implementation of the method of protection against poisoning carbon monoxide is injected into the body antidote reach due to the fact that the antidote representing 2,8,9-digitalnature - intramolecular Proc. of the cyclic complex of Tris(2-hydroxyethyl)amine (triethanolamine) with a zinc salt of an inorganic or organic acid composition is 1:1, administered orally. Before the introduction of the antidote is dissolved in 5% vol. the ethanol.

Comparative analysis of the prototype and patent-pending method of protection against poisoning by carbon monoxide shows that a common feature is only an introduction to the body zinc antidote.

A distinctive feature of the proposed method of protection from poisoning carbon monoxide is that patentable antidote representing 2,8,9-digitalnature - intramolecular tricyclic complex of Tris(2-hydroxyethyl)amine (triethanolamine) with a zinc salt of an inorganic or organic acid composition is 1:1, is introduced into the body orally.

The antidote is administered in a dose range of 20 to 60 mg/kg of body weight in the form of a solution in 5% vol. the ethanol.

The essence of the invention and the possibility of its realization explain the following examples of synthesis of the claimed zinc antidote CO and protection from poisoning by carbon monoxide from the use of this antidote.

Example 1. Obtaining zinc antidote "Citronen".

A mixture of 21.9 g of zinc acetate and 14.9 g of triethanolamine in 80 ml absolute ethanol is heated under stirring until complete dissolution. The hot solution is filtered and leave at room temperature until complete precipitation, and then filtered and repeatedly washed with ethanol, is then ether and dried in vacuum. Get a 32.6 g (98%) intramolecular tricyclic triethanolamine complex with zinc acetate in a ratio of 1:1 in the form of a white powder with TPL=142-143C. Found, %: C - 35,87; H - 6,50; N - 4,48; Zn - 19,47. Brutto-formula - C10H21O7NZn. Calculated, %: C - 36,10; H - 6,37; N - 4,21; Zn - 19,65.

Example 2. Obtaining complex based on a zinc salt of ortho-resocialise acid.

The mixture 16,62 g ortho-resocialise acid and 4,07 g of zinc oxide in 150 ml of benzene is heated under reflux with stirring for 8 hours the Precipitate is filtered and washed with ether. Received 19 g (96%) of the zinc salt of ortho-resocialise acid in the form of a colourless powder with TPL=Of 180.5-181C. Found, %: C - 54,37; H - 4,53; Zn - 16,40.

The mixture 19,79 g of zinc salt of ortho-resocialise acid and 7,46 g of triethanolamine in 150 ml absolute methanol is heated under stirring for 5 hours After removal of the solvent in vacuo the residue was washed with ether and dried in vacuum. The yield was 25 g (91,7%) intramolecular tricyclic triethanolamine complex with zinc salt of ortho-resocialise acid in the ratio of 1:1 with TPL=104-105C. Found, %: C - 52,56; H - 6,17; N - 3,00; Zn - 12,05. Brutto-formula - C24H33O9NZn. Calculated, %: C - 52,89; H - 6,11; N - 2.57 M; Zn - 12,00.

Example 3. Obtaining complex on the basis of chloride of zinc.

Analogously to example 1, with thematician, instead of zinc acetate taking 6.8 g of zinc chloride. Received 18,95 g (87.3 per cent) intramolecular tricyclic triethanolamine complex with zinc chloride in a ratio of 1:1 with TPL=227-228C. Found, %: C - 32,90; H - 7,40; N - 6,57; Cl - 15,9; Zn - 15,78. Brutto-formula - C12H30O6N2Cl2Zn. Calculated, %: C - 33,16; H - Of 6.96; N - 6,45; Cl - To 16.31; Zn - 15,04.

The authenticity of the chemical structure of the drugs confirmed by elemental analysis and NMR spectroscopy.

Example 4. Protection from poisoning by carbon monoxide from the use of the drug, "Citronen".

Pharmacological experiments were performed on nonlinear rats weighing 200-240 g Animals were divided into two groups (equal number of males and females in each group). 1 - control group, animals which anedotas protection is not received; 2 - "Citronen" in a dose of 40 mg/kg was administered orally 30 min before inhalation of carbon monoxide (CO concentration in the air was 5070 mg/m3). The experiments were conducted under conditions of dynamic dose of carbon monoxide in the seed chamber for 40 minutes

The solution antidote to 5% vol. ethanol was administered to the animals once using a metal probe. The signs of irritation of the gastrointestinal tract were observed. Also there was not a single case of death of the animals that received the antidote.

Efficiency of action is via antidote was determined by measuring the content of carboxyhemoglobin in the blood of animals. The level of carboxyhemoglobin in the blood of the animals of the control group was composed of 9.75% at the limit of 2-4 6-8%. In the blood of animals pre-treated with the antidote, the level of carboxyhemoglobin in the blood did not exceed 1.5 to 2.5%. The concentration of carboxyhemoglobin in the blood when using the proposed antidote compared to the control decreases 3.9-6.5 times. Patented antidote, anti-poisoning carbon monoxide, is much superior in its action prototype.

Example 5. The toxicity study "Tetrimino".

Toxicity Tetrimino" studied in nonlinear white mice and rats. Medium lethal dose by oral administration "Tetrimino" DL50are 51671000 mg/kg (mouse) and 55001250 mg/kg (rat). According to the American classification of medicinal substances (Hodge and Sterner) "Citronen" has the 5th degree of toxicity and applies to practically non-toxic medicines. According to GOST 12.1.007-76 (SSBT Harmful substances. Classification and General safety requirements "Citronen" refers to the 4th class of hazard (low hazard). Compared with this, the toxicity of the prototype several times higher (DL50780 (609-998) mg/kg).

As follows from the above review of the prior art, the claimed antidote, its structure, methods of preparation and use are brand new and originally the national, which points to the patentability of the invention. Declared the antidote, the method of its production and use are not derived from the famous still of information, that the proposed solutions are not obvious for specialists and inventive.

The invention allows to expand the range of a simple method for producing a highly secure (not shown side effects) drug protection, and prevention of poisoning by carbon monoxide. The proposed antidote shows strong detoxifying action and quickly removes animals from carbon monoxide poisoning.

Practical test "Tetrimino" protection from poisoning by carbon monoxide is allowed to prove experimentally that it is synthetically easily accessible and cost-effective, original medical means. The protective effect of the antidote based on the total manifestation of the properties of the cation and anion of the complex: the main antioxidant effect zikatanov cation [N(CH2CH2OH)3Zn]2+and the anion X-or Y2-shows additional therapeutic effect or remains inert.

1. The antidote of carbon monoxide, characterized in that the antidote is an intramolecular tricyclic triethanolamine complex with zinc the new salts of inorganic or organic acids.

2. The antidote of carbon monoxide according to claim 1, characterized in that the ratio of triethanolamine and zinc salts in the complex is 1:1.

3. The antidote of carbon monoxide according to claim 1, wherein the safener is applied in the form of an aqueous-alcohol solution.

4. The antidote of carbon monoxide according to claim 1, characterized in that the dose of the antidote is 20-60 mg/kg of body weight.

5. The way to protect against poisoning carbon monoxide is injected into the body of the antidote, characterized in that the injected antidote representing intramolecular tricyclic triethanolamine complex with zinc salt of an inorganic or organic acid.

6. The way to protect against poisoning carbon monoxide according to claim 5, characterized in that the ratio of triethanolamine and zinc salts in the complex is 1:1.

7. The way to protect against poisoning carbon monoxide according to claim 5, characterized in that the antidote is introduced into the body in the form of a water-alcohol solution, which is obtained by dissolving an antidote to 5% vol. the ethanol.

8. The way to protect against poisoning carbon monoxide according to claim 5, characterized in that the antidote is administered at a dose of 20-60 mg/kg of body weight.

9. The way to protect against poisoning carbon monoxide according to claim 5, characterized in that the antidote is administered orally.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to toxicology, and can be used for treating rats with acute verapamil intoxications. That is ensured by administering sodium thiosulphate 15-20 mg per 100 g of rat's weights as a cardioprotector.

EFFECT: method provides improved central venous pressure value.

3 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to zinc-containing antidote of lethal and severe poisonings with ethanol. Claimed antidote represents intramolecular tricyclic complex of triethanolamine with zinc salts of inorganic or organic acids (2, 8, 9-trihydrozincatran), the ratio of triethanolamine to zinc salts being 1:1. Invention also relates to method of treating ethanol poisoning by introduction into organism of zinc-containing antidote in 5 vol.% ethanol in dose range 30-60 mg/kg of body weight.

EFFECT: prevention of lethal outcome in case of ethanol poisoning and reduction of acute toxicity of zinc-containing antidote.

9 cl, 5 ex

FIELD: chemistry.

SUBSTANCE: Chinese magnolia is extracted with liquefied carbon dioxide. The obtained CO2 extract undergoes chromatographic separation on aluminium oxide and eluated with hexane. After eluation the obtained hexane fractions are frozen and recrystallised from the chloroform-hexane mixture in ratio of 1:10-3:10.

EFFECT: high output of product.

1 ex

FIELD: medicine; veterinary science.

SUBSTANCE: method consists in introduction to an experimental animal of Acyzol 30 mg/kg once a day combined with daily subcutaneous introduction of cadmium sulphate solution in a dose 0.1 mg/kg.

EFFECT: prevention of cadmium toxic effect in chronic poisoning in experimental animals.

2 cl, 1 tbl, 1 ex

Medicinal agent // 2363463

FIELD: medicine.

SUBSTANCE: invention relates to medicine and pharmaceutical industry, and more specifically to making tableted dosage form with prophylactic effect for arresting primed reaction to radiation and early transient incapacity. The agent contains ondansetron, methacin and caffeine in weight ratio ondansetron:methacin:caffeine 4:1:20-300.

EFFECT: reduced adverse reaction, more specifically vomiting, diarrhea and reduction of physical activity.

5 cl, 11 tbl

FIELD: medicine.

SUBSTANCE: claimed is remedy possessing antitoxic properties in case of aliphatic alcohol poisoning. As such polyosm - 30% solution of polyethylene oxide 400 is suggested. It is shown that polyosm protects animals against death (100% in control) in case of isopropyl alcohol poisoning.

EFFECT: water content in lungs is analogous to index of intact animals at moderate reduction of respiration rate.

6 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention refers to veterinary science, in particular to products intended to increase capacity for survival and yield of poultry. For this purpose common composition 1,3-di(3-piperidine-2-hydroxypropyl)-6-methyluracil of formula: is used. Composition is characterised by natural resistance, antioxidant activity, activates nonspecific factors of immune system, as well as possesses medicinal properties to provide detoxification of nitrates and nitrites. Composition has the appearance of white powder, is highly soluble in water and can be added in specified doses to chickenfeed.

EFFECT: production of composition providing increase of capacity for survival and yield of poultry.

6 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and deals with acizol application as preventive and therapeutic means in neurotoxin poisoning cases. The present invention showed high efficacy of acizol in complex treatment for toxico-hypoxic encephalopathy and pneumonia (normalisation of homeostasis indices, lowering of mortality and disabling complications).

EFFECT: lowering of the risk of complications in neurotoxin poisoning cases.

15 tbl

FIELD: medicine; pharmacology.

SUBSTANCE: wood of Siberian or Daurian larch is debarked, cleaved and dried at 40-50°C to residual moisture 23-27%. Dried wood is chopped, and soluble substances are extracted with 75-85% ethyl alcohol aqueous solution at temperature 45-50°C in ratio raw material:extracting agent 1:(7-10). Further extracting agent is distilled off, and sawdust is supplied to press for additional alcohol return. Then extract aqueous part is cooled to 20-25°C within 20-30 minutes for isolation of resinous impurity accompanying dihydroquercetin (DHQ). Deresined extract aqueous part is added with methyltertbutyl ether (MTBE) in ratio 1: (0.3-0.45), and DHQ is reextracted within 2-3 hours. Extract ether part is isolated separate from aqueous part through sedimentation within 2-2.5 hours and supplied to MTBE evaporation, while target product is crystallised of hot water. Invention enables to produce DHQ with yield 2.2-2.5% of bone-dry wood mass with grade 90-96%.

EFFECT: simplification of process and production of high-quality product.

4 cl, 2 ex

FIELD: medicine; veterinary.

SUBSTANCE: method describes the use of 2,4-diphenyl-7,8-benzo-5,6-dihydroselenochromen as a means of treatment and prevention of poisoning with heavy metal compounds.

EFFECT: higher resistance in animals and humans to poisoning with heavy-metal compounds.

8 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine, namely to anti-tuberculosis composition. Claimed is pharmaceutical composition which includes sodium salt of para-aminosalicylic acid, zinc sulfate, sorbitol, polyvinylpyrrolodone, citric acid, stearic acid salt, sodium carboxymethyl starch, colloidal silicon dioxide and polyethylene glycol in amounts stated in invention formula.

EFFECT: pharmaceutical composition is characterised by high therapeutic activity, satisfactory technological characteristics and has storage term more than 2 years.

8 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an infusion solution for total blood volume replacement, hydro-electrolytic rebalancing, trace recovery, and hematopoiesis process normalisation. The declared solution contains sodium, potassium, calcium, magnesium, chloride and acetate ions with water, and in addition it contains cobalt, zinc and manganese ions in the following proportions, mmole: Na+ -140; K+ - 4; Ca++ - 2,5; Mg++ - 1; Co++ - 0.0006; Zn++ - 0.022; Mn++ - 0.004; CI- - 111; CH3COO- - 40; and water for injections up to 1 l.

EFFECT: solution is balanced in relation to an ionic composition of human blood plasma and effects on erythropoiesis stimulation.

8 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, namely to creation of composition of dense extract of conifer needles for capsulation. Composition of dense extract of conifer needles contains the following ingredients: dense extract of conifer needles, emulsifier, a-tocopherol (vitamin E), retinol (vitamin A), naphthoquinones (vitamin K), essential fatty acids (vitamin F), vegetable oil. Microelements can be included additionally.

EFFECT: composition improves state of mucous membranes and enhances protective properties of organism.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to zinc-containing antidote of lethal and severe poisonings with ethanol. Claimed antidote represents intramolecular tricyclic complex of triethanolamine with zinc salts of inorganic or organic acids (2, 8, 9-trihydrozincatran), the ratio of triethanolamine to zinc salts being 1:1. Invention also relates to method of treating ethanol poisoning by introduction into organism of zinc-containing antidote in 5 vol.% ethanol in dose range 30-60 mg/kg of body weight.

EFFECT: prevention of lethal outcome in case of ethanol poisoning and reduction of acute toxicity of zinc-containing antidote.

9 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to agents for treating locomotive diseases in human and animals. The agent represents a colloidal solution of an aqueous suspension of a sea mineral composition of microparticle size 106-107 m with an active surface of micelle microparticles no more than 500 m2/ml and density of the aqueous suspension not exceeding 1.7 kg/l, in the following proportions, wt %: mineral composition 58, water - the rest; the mineral composition contains solid macroelements - chemical chalk and magnesium carbonate, and microelements: zinc, iron, silicon, copper, iodine, etc. in the certain proportions.

EFFECT: use of the agent provides increasing blood serum calcium, magnesium and phosphate levels in the cases only when observing the deficiency of said elements either due to age-related mineral metabolism or resulted from the presence of any diseases, however does not cause a material overcritical increase of blood calcium, but normalises it and besides promotes considerable reduction of synosteosis length.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to composition with fixed dose of phytate and zinc in form of Zn2+ cation for production of medication for treatment of calcification, formed as a result of hydroxyapatite crystallisation, in particularly for prophylaxis and/or prevention of hydroxyapatite crystallisation in people. Synergism of action of composition components is shown, as a result of zinc adsorption on formed hydroxyapatite crystallisation core, which increases affinity of phytate to growing crystal, enhancing its inhibitory action on crystallisation.

EFFECT: composition increases affinity of phytate to growing crystal, enhancing its inhibitory action on crystallisation.

11 cl, 3 dwg, 2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary. Bactericidal composition for prevention and treatment of infectious diseases of hoofs in animals, includes stabilised sol of copper, zinc and silver nanoparticles, methylene blue, as well as polyethyleneglycole-4000, polyvinylpyrrollidone, cellulose, formic and lactic acids, purified water with specified component ratio.

EFFECT: invention ensures increase of anti-microbial activity and improvement of composition storing terms.

6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatology and can be applied for eczema treatment. For this purpose additionally to complex drug therapy administered is seramil intramuscularly in dose 0.5 mg every second day. Treatment course consists of 10 days.

EFFECT: method provides effective treatment, absence of side effects, reduction of recurrence number, stable remission, accompanied by normalisation of immune system and reduction of treatment terms.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an antituberculous composition which can represent a solid dosage form containing a therapeutically effective amount of an active principle - a combination of sodium paraaminosalicylate (PAS) and zinc sulphate.

EFFECT: invention provides a synergetic effect which consists in higher antimycobacterial activity and enabled therapy of drug resistant forms of tuberculosis complicated by pulmonary tissue destruction.

9 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmacy, namely to creation of complexes for treatment of chronic fatigue syndrome (CFS). Four naturopathic complexes for CFS treatment contain herbal mixtures and homeopathic medications.

EFFECT: intake of naturopathic complexes ensures high therapeutic effect throughout the treatment without negative side effects and disease recurrences.

5 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to methods and compositions wherein low concentration of zinc salts combinations and antimicrobial agents are used for medical device coating.

EFFECT: coatings exhibit counterirritant effect and inhibit vectors of an infectious disease.

18 cl, 4 tbl

Up!